New TMF Maturity Model from Veeva Systems Offers Expert Guidance on Developing and Executing a Strategy to Improve TMF Business Operations
Consultative service, online or in-person, provides life sciences organizations with TMF roadmap
PLEASANTON, CA – Jan. 21, 2016– Veeva Systems introduces the Veeva TMF Maturity Model – a complimentary consultative service designed to assess the state of a life sciences organization’s trial master file (TMF) strategy and provide a roadmap for improvement. The Veeva TMF Maturity Model gives practical, step-by-step guidance to help companies transform their TMF from a static archive into a strategic asset that can help increase the efficiency of clinical trials. It is available as a self-service online tool or as a more detailed, in-person evaluation with a seasoned subject matter expert.
The Veeva TMF Maturity Model assessment provides companies with a tailored report, outlining the current state of their TMF, comparison to industry benchmarks, and a roadmap for improvement. More than 60 life sciences companies have already completed the evaluation.
Data amassed to date shows companies who have completed the Veeva TMF Maturity Model evaluation are only halfway along the full TMF maturity curve, averaging 2.54 on a scale of one to five. These empirical findings are consistent with industry-wide survey data from the annual Veeva 2015Paperless TMF Survey showing an industry shift away from maintaining paper documentation, however, with still too much reliance on manual processes. More than half of survey respondents (59%) report archiving documents electronically, yet far fewer have fully digitized other key activities such as e-signatures (21%), document creation (25%), and collaboration (30%).
“In just one year, the industry has seen a dramatic uptick in electronic TMF application adoption,” said Jason Methia, director of Vault eTMF strategy at Veeva. “The Veeva TMF Maturity Model provides the industry with a reliable framework to make systematic strides towards shedding paper and transitioning toward automated methods and systems.” Kathryn King, vice president of Vault Clinical at Veeva, will discuss how to move along the TMF continuum during ExL Pharma’s 5th Trial Master File Summit, at 10:45 AM on January 21, 2016 at the Westin Arlington Gateway in Virginia.
Life sciences organizations can visit VeevaTMFmaturity.com to access the self-service Veeva TMF Maturity Model or email TMFMaturity@veeva.com to request a one-on-one assessment.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
